Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Anteris Technologies Global Corp. Interim / Quarterly Report 2012

Feb 29, 2012

33869_rns_2012-02-29_3fa35d2a-7dce-45e4-835c-5133296dfcb5.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [595 x 114] intentionally omitted <==

ASX RELEASE

29 February 2012

ASX Market Announcements Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Half Yearly Report (Appendix 4D) for the 6 months ended 31 Dec 2011 Programs show good progress

Allied Healthcare invested further into Professor Ian Frazer’s vaccine company Coridon Revenue of over $3.6M from the distribution business

  • The Directors of Allied Healthcare Group Limited (the "Company") are pleased to announce the operating results of the Company for the 6 months ended 31 December 2011. The current period accounts represent the consolidation of Allied Healthcare Group Investments Pty Ltd ( formerly Allied Medical Limited ) (and subsidiaries) and Allied Healthcare Group Limited ( formerly bioMD Limited ) (and subsidiary).

  • Over the past 6 months the merger has been completed between the two groups with the ASX listed company now to be known as Allied Healthcare Group Limited (www.alliedhealthcaregroup.com.au). The overall loss for the period was $1.91M which includes costs associated with the merger and the consolidation of the two groups plus the increased activities around the regulatory filing for the Celxcel Pty Limited for the approval of the ADAPT technology and the Group’s share of losses from investment company Coridon Pty Limited.

The highlights for the 6 month period were:

  • The successful merger of the Group.

  • The company raised capital of $2.2M in a placement as part of the merger process. These funds were used to:

  • Increase the Allied Healthcare Group Limited ownership percentage of Coridon Pty Limited, a company founded by Professor Ian Frazer with a focus on next generation vaccines

  • Increase inventory for Allied Medical Pty Limited which had stronger sales compared to the previous 12 months

  • The Net Tangible Assets (NTA) decreased overall due to the stock swap merger between the two companies resulting in a dilution affect rather than decrease in the assets of the company.

ABN 35 088 221 078 Level 1, 197 Adelaide Terrace Perth Western Australia 6000 PO Box 6879 East Perth Western Australia 6892 T +61 (0) 8 9385 5038 F +61 (0) 8 9385 5028 E [email protected]

www.alliedhealthcaregroup.com.au

  • Overall liabilities were reduced by 20% while net assets were increased over the period.

  • Strengthened the management team with the appointments of Mr Bob Atwill as CEO of Celxcel Pty Limited and executive at Allied Healthcare Group and Dr Julian Chick as COO of the Allied Healthcare Group Limited.

  • The sales for the distribution businesses for the current period were $3.643 million, up from $3.557 in the corresponding period of the previous year. The total profit margin was down slightly for the period due to re-assignment of sales force focus which is expected to result in a stronger second half.

  • Expiry of 72.9 million listed options on 31 December 2011.

Over the past 6 months the company has continued to pursue the Celxcel Pty Limited technology towards approval in major jurisdictions. The company is expecting to release updates on the regulatory progress on Australian, European and the US in the coming 6 months. Several studies have been undertaken and the company expects to release updates and results in the next 6 months.

In addition during the past 6 months, Coridon Pty Limited showed significant animal results in its Herpes vaccine study which demonstrated clearance of the virus. The program is now progressing towards an initial Phase I study which is scheduled to start in the second half of 2012.

Overall Allied Medical Pty Limited remains in a strong position and increased inventory has been built up ahead of the typically stronger second half of the year. Allied Medical Pty Limited maintains one of the largest infusion product portfolios in the Australian market.

The following half yearly report includes:

  • Appendix 4D;

  • Directors’ Report;

  • Financial Report;

  • Directors’ Declaration; and

  • Audit Report and Independence Declaration.

Yours faithfully

==> picture [112 x 58] intentionally omitted <==

Stephen Mann Company Secretary

Appendix 4D

Half Yearly Report

Name of Entity:

ABN: Reporting Period: Previous corresponding Period:

Allied Healthcare Group Limited 35 088 221 078 Half year ended 31 December 2011 Half year ended 31 December 2010

Results for Announcement to the Market

$A’000
Revenues from ordinary activities down 6.6% to 3,321
Loss from ordinary activities after tax down 134.1% to (1,918)
Loss for the period attributable to members down 127.8% to (1,866)
Dividends Amount per
security
Franked amount
per security
Interim dividend NIL¢ NIL¢
Previous corresponding period NIL¢ NIL¢

Results Commentary

The overall loss for the equity holders of Allied Healthcare Group Limited was $1,866.068, compared to $819,193 for the previous period. The 2011 loss is for the post-merger consolidated group compared to the 2010 figure which is only for the Allied Healthcare Group Investments Limited group ( formerly Allied Medical Limited ) and included expense of $790,851 for the impairment of goodwill in Medevco Pty Limited.

The loss for the period is mainly attributed to costs associated with the merger and the recent regulatory activities relating to approval of the Celxcel Pty Limited technology and the Group’s share of losses from investment company Coridon Pty Limited.

Overall during the period the company made significant progress on the approval process for the Celxcel Pty Limited technology, including filing for approval for the CardioCel product with the Therapeutic Goods Administration (TGA) in Australia as well as planning for European and US approval. The company expects to provide further updates on the regulatory approval application progress over the coming 6 months.

During the period the Allied Medical Pty Limited continued to show a strong business, with sales from the business reaching $3.6 million for the period.

Also during the period Group also increased its investment into Coridon Pty Limited after positive animal study results. Coridon Pty Limited reported clearance of herpes virus in the study. Coridon Pty Limited is currently preparing to progress the herpes vaccine program into the initial human clinical study later in 2012.

Net Tangible Assets per security

Current period Previous
corresponding period
Net tangible asset backing per ordinary security 0.87 cents per share 2.31 cents per share

The change in the Net Tangible Assets per security between the previous corresponding period and the current period can be attributed to the dilution due to merger between Allied Healthcare Group Investments Pty Limited and Allied Healthcare Group Limited. The NTA does not recognise any goodwill attributed to the Allied Healthcare Group Limited business.

Control gained over entities having material effect

N/A

Loss of control of entities having material effect

N/A

Details of aggregate share of profits (losses) of associated and joint venture entities

N/A

This report is based on:

The accounts have been subject to review.

==> picture [88 x 46] intentionally omitted <==

Sign here: (Company Secretary)

Date: 29 February 2012

Print name: Stephen Mann

==> picture [183 x 99] intentionally omitted <==

(ACN 088 221 078)

CONSOLIDATED HALF-YEAR FINANCIAL REPORT

31 DECEMBER 2011

==> picture [596 x 114] intentionally omitted <==

CORPORATE DIRECTORY

Directors

Christopher J. Catlow – Non Executive Chairman Lee E. Rodne – Managing Director Michael C. Bennett – Executive Director William G. Rowley – Non-executive Director Handojo (Jet) Soedirdja – Non-executive Director Robert E. Towner – Non-executive Director

Company Secretary

Stephen Mann

Company and Registered Office

Level 1, 197 Adelaide Terrace Perth, Western Australia 6000 Telephone: +61 8 9266 0100 Facsimile: +61 8 9266 0199 Website: www.alliedhealthcaregroup.com.au Email: [email protected]

Auditors

BDO Audit (WA) Pty Ltd 38 Station Street Subiaco, Western Australia 6008

Solicitors

Hardy Bowen Lawyers 1/28 Ord Street West Perth, Western Australia 6005

Bankers

ANZ 77 St Georges Terrace Perth, Western Australia 6000

Stock Exchange Listing

Australian Stock Exchange codes: AHZ (ordinary shares)

2

==> picture [595 x 114] intentionally omitted <==

DIRECTORS’ REPORT

The Directors present the half-yearly financial report on the consolidated entity (referred to hereafter as the ‘Consolidated Entity’ or ‘Group’) consisting of Allied Healthcare Group Limited and its controlled entities for the half-year ended 31 December 2011.

DIRECTORS

The following persons were Directors of the Company during the half-year and up to the date of this report:

Christopher J. Catlow

Lee E. Rodne Michael C. Bennett William G. Rowley Handojo (Jet) Soedirdja Robert E. Towner

Stephen Mann was appointed Company Secretary on 20 October 2011, Darren Bromley resigned on the same date.

PRINCIPAL ACTIVITIES

The principal activities of the Group during the half-year consisted of:

  • The distribution business is focused on infusion and cardiology products used in hospital and ambulatory care. Allied Medical Pty Limited has a large portfolio of infusion and cardio related products in Australia and has seen strong growth in revenue over the past few years.

  • Continued progression of the Celxcel Pty Limited’s ADAPT technology, with a particular focus on an initial approval for the technology. Celxcel Pty Limited progressed the filing of the CardioCel technology with the TGA as well as initiating discussions on regulatory approval in Europe and the US.

  • � During the half year the Group increased its investment into Coridon Pty Limited, a company focused on developing DNA vaccines as the next generation vaccines. During the period Coridon Pty Limited reported results from a very successful herpes animal study which showed 100% clearance of the virus. Coridon Pty Limited is currently planning to initiate a Phase I study for the herpes vaccine program later in 2012.

REVIEW OF OPERATIONS AND RESULTS

The consolidat e d operating loss for the half-year:

31 Dec 2011
$
31 Dec 2010
$
Loss before income tax (1,952,397) (754,454)
Income tax benefit / (expense) 34,882 (64,739)
Loss for the period (1,917,515) (819,193)

3

==> picture [595 x 115] intentionally omitted <==

DIRECTORS’ REPORT (continued)

The overall loss for the equity holders of Allied Healthcare Group Limited was $1,866,068, compared to $819,193 for the previous period. The 2011 loss is for the post-merger consolidated group compared to the 2010 figure which is only for the Allied Healthcare Group Investments Limited ( formerly Allied Medical Limited ) group and included expense of $790,851 for the impairment of goodwill in Medevco Pty Limited.

The loss for the period is mainly attributed to costs associated with the merger and the recent regulatory activities relating to approval of the Celxcel Pty Limited technology and the Group’s share of losses from investment company Coridon Pty Limited.

Overall during the period the company made significant progress on the approval process for the Celxcel Pty Limited technology, including filing for approval for the CardioCel product with the Therapeutic Goods Administration (TGA) in Australia as well as planning for European and US approval. The company expects to provide further updates on the regulatory approval application progress over the coming 6 months.

During the period the Allied Medical Pty Limited continued to show a strong business, with sales from the business reaching $3.6 million for the period.

Also during the period Group also increased its investment into Coridon Pty Limited after positive animal study results. Coridon Pty Limited reported clearance of herpes virus in the study. Coridon Pty Limited is currently preparing to progress the herpes vaccine program into the initial human clinical study later in 2012.

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

No significant changes have occurred in the state of affairs of the consolidated entity.

DIVIDENDS

No dividend was paid during the half-year and the Board has not recommended the payment of a dividend.

EVENTS SUBSEQUENT TO REPORTING DATE

On 12 January 2012, the Company issued 3,641,911 shares upon the exercise of 3,641,911 listed options at $0.04 to raise $145,676. The Company also announced the lapse of the remaining 72,691,484 listed options which expired 31 December 2011.

AUDITORS INDEPENDENCE DECLARATION

Section 307C of the Corporations Act 2001 requires our auditors, BDO Audit (WA) Pty Ltd, to provide the directors of the company with an Independence Declaration in relation to the review of the interim financial report. This Independence Declaration is set out on page 5 and forms part of this directors’ report for the half-year ended 31 December 2011.

This report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

==> picture [109 x 40] intentionally omitted <==

Christopher J Catlow Chairman

Dated at Perth, Western Australia this 29[th] day of February 2012.

4

38 Station Street Subiaco, WA 6008 PO Box 700 West Perth WA 6872 Australia

Tel: +8 6382 4600 Fax: +8 6382 4601 www.bdo.com.au

==> picture [77 x 30] intentionally omitted <==

29 February 2012

The Board of Directors Allied Healthcare Group Limited Level 1, 197 Adelaide Tce, PERTH WA 6000

Dear Sirs,

DECLARATION OF INDEPENDENCE BY BRAD MCVEIGH TO THE DIRECTORS OF ALLIED HEALTHCARE GROUP LIMITED

As lead auditor of Allied Healthcare Group Limited for the period ended 31 December 2011, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

  • the auditor independence requirements of the Corporations Act 2001 in relation to the halfyear review; and

  • any applicable code of professional conduct in relation to the review.

This declaration is in respect of Allied Healthcare Group Limited and the entities it controlled during the period.

==> picture [69 x 47] intentionally omitted <==

Brad McVeigh Director

BDO Audit (WA) Pty Ltd

Perth, Western Australia

BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO (Australia) Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO (Australia) Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation (other than for the acts or omissions of financial services licensees) in each State or Territory other than Tasmania.

5

==> picture [595 x 115] intentionally omitted <==

STATEMENT OF COMPREHENSIVE INCOME FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

CONSOLIDATED

CONSOLIDATED
Note
Revenue from continuing operations
2
Cost of sales
Gross Profit
Other income
Administrative expenses
Employee benefits
Consultancy fees
Travel costs
Share based payments
Impairment expense
Asset write-down
Loss from equity accounting
7
Depreciation expense
Loss before income tax from
continuing operations
Income tax benefit / (expense)
Loss for the half-year
Other comprehensive income for the half-year
Total comprehensive loss for the half-year
Total comprehensive loss for the half-year is
attributable to
Equity holders of Allied Healthcare Group Limited
Non controlling interests
Loss per share (cents per share) from continuing
operations attributable to ordinary equity holders of
the Company
Basic loss per share
Diluted loss per share
The above Consolidated Statement of Comprehensive Income
accompanying notes.
Note 31 Dec 2011
$
31 Dec 2010
$
2 3,320,856
3,557,300
(1,794,276)
(1,917,882)
1,526,580
1,639,418
12,881
60,280
(875,048)
(313,328)
(1,260,664)
(905,472)
(665,117)
(98,426)
(181,087)
(93,432)
(102,000)
(250,000)
-
(790,851)
(48,898)
-
(344,961)
-
(14,083)
(2,643)
(1,952,397)
(754,454)
34,882
(64,739)
(1,917,515)
(819,193)
-
-
(1,917,515)
(819,193)
(1,866,068)
(819,193)
(51,447)
-
(1,917,515)
(819,193)
Cents
Cents
(0.322)
(0.132)
N/A
N/A
should be read in conjunction with the

6

STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2011

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2011
ASSETS
Current assets
Cash and cash equivalents
Trade and other receivables
Inventories
Income tax receivable
Total current assets
Non-current assets
Investments accounted for using the equity method
Property, plant & equipment
Intangible assets
Deferred tax asset
Total non-current assets
Total assets
LIABILITIES
Current liabilities
Trade and other payables
Provisions
Current tax payable
Total current liabilities
Non-current liabilities
Provisions
Borrowings
Total non-current liabilities
Total liabilities
NET ASSETS
EQUITY
Contributed equity
Reserves
Accumulated losses
Capital and reserves attributable to equity holders of
Allied Healthcare Group Limited
Non controlling interest
TOTAL EQUITY
Note CONSOLIDATED
31 Dec 2011
$
30 June 2011
$
7
8
9
605,920
1,354,254
1,690,631
11,199
3,662,004
2,270,394
137,058
8,962,545
167,341
11,537,338
15,199,342
570,352
201,273
-

771,625
99,437
20,054
119,491
891,116
14,308,226
16,219,674
752,420
(2,611,568)
14,360,526
(52,300)
14,308,226
1,351,518
1,217,279
1,722,341
-
4,291,138
1,245,355
132,846
8,947,399
131,441
10,457,041
14,748,179
808,652
160,192

24,224
993,068
96,624
20,054
116,678
1,109,746
13,638,433
13,925,166
459,620
(745,500)
13,639,286
(853)
13,638,433

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.

7

==> picture [595 x 114] intentionally omitted <==

STATEMENT OF CHANGES IN EQUITY FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

CONSOLIDATED

CONSOLIDATED
Share
Capital
$
Share-
based
payment
Reserves
$
Accum
Losses
$
Total
$
Non
controlling
Interest
$
Total Equity
$
Balance at 1 July 2010
Loss for the period
Total comprehensive loss for the
half-year
Transactions with owners in
their capacity as owners
Shares issued during the period
Balance at 31 December 2010
Balance at 1 July 2011
Loss for the period
Total comprehensive loss for the
half-year
Transactions with owners in
their capacity as owners
Shares issued during the period
Options issued during the period
Shares issued to set-up equity
facility
Capital raising costs
Exercise of options
Balance at 31 December 2011
29,914
-
1,207,295
1,237,209
-
1,237,209
-
-
(819,193)
(819,193)
-
(819,193)
-
-
(819,193)
(819,193)
-
(819,193)
3,046,850
-
-
3,046,850
-
3,046,850
3,076,764
-
388,102
3,464,866
-
3,464,866
13,925,166
459,620
(745,500)
13,639,286
(853)
13,638,433
-
-
(1,866,068)
(1,866,068)
(51,447)
(1,917,515)
-
-
(1,866,068)
(1,866,068)
(51,447)
(1,917,515)
2,201,451
-
-
2,201,451
-
2,201,451
102,000
-
102,000
-
102,000
-
190,800
-
190,800
-
190,800
(210,399)
-
-
(210,399)
-
(210,399)
303,456
-
-
303,456
-
303,456
16,219,674
752,420
(2,611,568)
14,360,526
(52,300)
14,308,226

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

8

==> picture [595 x 114] intentionally omitted <==

STATEMENT OF CASH FLOWS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

Cash flows from operating activities
Receipts from customers
Payments to suppliers
Interest received
Interest paid
Income tax paid
Net cash outflow from operating activities
Cash flows from investing activities
Payments for property, plant & equipment
Purchase of equity accounted investments
Payments for intangible assets
Net cash outflow from investing activities
Cash flows from financing activities
Proceeds from issue of shares
Proceeds from exercise of options
Share issue transaction costs
Net cash inflow from financing activities
Net decrease in cash held
Cash at the beginning of the half-year
Cash at end of the half-year
CONSOLIDATED
Half-year
31 Dec 2011
$
Half-year
31 Dec 2010
$
CONSOLIDATED
Half-year
31 Dec 2011
$
Half-year
31 Dec 2010
$
3,215,207
(4,894,679)
(1,679,472)
14,294
(7,393)
(36,441)
(1,709,012)
(18,296)
(1,370,000)
(15,146)
(1,403,442)
2,207,261
278,047
(118,452)
2,366,856
(745,598)
1,351,518
605,920
2,927,888
(3,720,251)
(792,363)
9,041
-
(153,150)
(936,472)
-
(900,000)
-
(900,000)
2,199,427
(77,558)
2,121,869
285,397
378,529
663,926

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

9

==> picture [595 x 115] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The half-year financial report is a general-purpose financial report, which has been prepared in accordance with the Corporations Act 2001 and Accounting Standard AASB 134 Interim Financial Reporting . The halfyear financial report has been prepared in accordance with the historical cost convention.

This half-year financial report does not include all the notes of the type normally included within the annual financial report and accordingly, this report should be read in conjunction with the annual financial report for the year ended 30 June 2011 and any public announcements made by Allied Healthcare Group Limited during the interim period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

2. REVENUES

Revenue from continuing operations
Sales
Total revenue from continuing operations
Breakdown of Other Revenue
Bank interest
Other income
Half-year
2011
$
3,320,856
3,320,856
14,294
(1,413)
**12,881 **
Half-year
2010
$
3,557,300
3,557,300
9,041
51,239
60,280

3. EXPENSES

Loss for the half-year before income tax includes the following specific expenses:

Half-year Half-year
2011 2010
$ $
Consultancy fees 665,117 98,426
Travel costs 181,087 93,432
Depreciation – Plant and equipment 14,083 2,643
Impairment expense - 790,851
Asset write-downs 48,898 -
Employee benefits expense
Salary and wages 1,105,180 810,245
Leave provisions 82,011 62,712
Other benefits 73,473 32,515

10

==> picture [595 x 115] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

4. SUBSEQUENT EVENTS

On 12 January 2012, the Company issued 3,641,911 shares upon the exercise of 3,641,911 listed options at $0.04 to raise $145,676. The Company also announced the lapse of the remaining 72,691,484 listed options which expired 31 December 2011.

5. SEGMENT INFORMATION

Description of segments

In accordance with AASB 8 Operating Segments, segment information is presented using a management approach, i.e. segment information is provided on the same basis as information as used for internal reporting purposes by the chief operating decision makers (board of directors that make key strategic decisions).

Management has determined that there are two identifiable reportable segments as follows:

  • Disposable medical products and medical devices distribution; and

  • Bioimplants operations of Celxcel Pty Ltd.

Total segment revenue
Segment profit / loss
before income tax
Segment assets
Segment liabilities
Medical products
& devices
Bioimplants
Unallocated
Total
Dec 2011
$
Dec 2010
$ Dec 2011
$
Dec 2010
$ Dec 2011
$
Dec 2010
$ Dec 2011
$
Dec 2010
$
3,642,856
3,557,300
-
-
(322,000)
-
3,320,856
3,557,300
29,902
36,397
(227,137)
-
(1,755,162)
(790,851)
(1,952,397)
(754,454)
Dec 2011
$
Jun 2011
$ Dec 2011
$
Jun 2011
$ Dec 2011
$
Jun 2011
$ Dec 2011
$
Jun 2011
$
5,770,624
4,913,634
90,106
161,281
9,338,612
9,673,264
15,199,342
14,748,179
2,002,260
753,143
199,291
43,329
(1,310,435)
313,274
891,116
1,109,746

11

==> picture [595 x 114] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

5. SEGMENT INFORMATION (continued)

Performance is measured based on segment result before tax.

The reconciliation of segment information to loss for the half-year is as follows:

CONSOLIDATED

Segment profit (loss)
Other revenue
Administration costs
Consultancy fees
Employee costs
Travel costs
Impairment expense
Loss from equity accounting
Share based payments
Loss for the half-year before income tax
Dec 2011
$
(197,235)
9,632
(754,901)
(494,730)
(29,318)
(38,884)
-
(344,961)
(102,000)
(1,952,397)
Dec 2010
$
36,397
-
-
-
-
-
(790,851)
-
-
(754,454)

6. DIVIDENDS

No dividends have been declared or paid during the period.

7. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

Investments
Investment in Coridon (unlisted security)
Movement
Opening balances
Additional investment
Disposals
Asset write-down
Loss from equity accounting
Closing balance
31 December
2011
$
2,270,394
1,245,355
1,370,000
-
-
(344,961)
2,270,394
30 June
2011
$
1,245,355
-
1,430,000
-
-
(184,645)
1,245,355

12

==> picture [595 x 114] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

8. CONTRIBUTED EQUITY

(a)
Share Capital
Ordinary shares
Fully paid
Movements in Ordinary Share Capital
Opening balance
Options exercised
Shares issued for associated costs with
set-up of equity facility
Shares issued in relation to business
combination
Share placement
Capital raising costs
Closing balance
SHARES
$
31 December
2011
31 December
2010
31 December
2011
31 December
2010
656,382,383
10,504,534
16,219,674
3,076,764
564,561,349
4,410,835
13,925,166
29,914
7,586,412
-
303,456
-
5,611,765
-
(190,800)
-
-
847,423
423,712
78,622,857
5,246,276
2,201,451
2,623,138
-
-
(19,599)
-
656,382,383
10,504,534
16,219,674
3,076,764

13

==> picture [595 x 115] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

9. RESERVES

Share based payments reserve
Movement
Opening balances
Share issued to set-up Kodiak equity facility
Options issued to Bell Potter
Closing balance
31 December
2011
$
752,420
459,620
190,800
102,000
752,420
30 June
2011
$
459,620
-
-
459,620
459,620

Share based payments reserve consists of 5,611,765 shares issued to Kodiak Capital Group LLC as commitment shares post signing agreement to set-up equity facility to provide the Group funding of up to US$3,000,000 drawn down in parcels of US$500,000 at the Group’s discretion. The reserve also consist of 6,000,000 unlisted options exercisable at $0.06 expiring on 20 October 2014 issued to Bell Potter Securities Limited in accordance with agreement for Placement.

Fair Value of Options Granted

The assessed fair value at grant date of options granted during the period ended 31 December 2011 was 1.7 cents per option. The fair value at grant date is independently determined using a Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option.

The model inputs for options granted during the period ended 31 December 2011 included:

  • (a) options are granted for no consideration and vest based on holder still being employed by Allied Healthcare Group Limited over a three year period. Vested options are exercisable for a period up to expiry date.

  • (b) exercise price: $0.06

  • (c) grant date: 20 October 2011

  • (d) expiry date: 20 October 2014

  • (e) share price at grant date: $0.036

  • (f) expected price volatility of the company's shares: 90%

  • (g) risk-free interest rate: 3.88%

The expected price volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information.

14

==> picture [595 x 115] intentionally omitted <==

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2011

10. COMMITMENTS

Total expenditure commitments at reporting date not provided for in the financial statements.

(a)
Operating Lease Commitments
Future operating lease commitments not provided for in the financial
statements and payable:
Within one year
Later than one year but no later than five years
The Company leases office space under an operating lease that
expires in May 2013 with option for additional 2 years.
CONSOLIDATED
31 December
2011
$
30 June
2011
$
104,671
-
53,109
-
157,780
-

15

==> picture [595 x 115] intentionally omitted <==

DIRECTORS’ DECLARATION

In the Directors’ opinion:

  • (a) the financial statements of the consolidated entity are in accordance with the Corporations Act 2001; including:

  • (i) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001 and other mandatory professional requirements, and

  • (ii) giving a true and fair view of the consolidated entity’s financial position as at 31 December 2011 and of its performance for the half-year ended on that date; and

  • (b) there are reasonable grounds to believe that Allied Healthcare Group Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors.

==> picture [109 x 40] intentionally omitted <==

Christopher J. Catlow Chairman

Perth, Western Australia

Dated this 29[th] day of February 2012

16

38 Station Street Subiaco, WA 6008 PO Box 700 West Perth WA 6872 Australia

Tel: +8 6382 4600 Fax: +8 6382 4601 www.bdo.com.au

==> picture [75 x 29] intentionally omitted <==

INDEPENDENT AUDITOR’S REVIEW REPORT TO THE MEMBERS OF ALLIED HEALTHCARE GROUP LIMITED

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Allied Healthcare Group Limited, which comprises the statement of financial position as at 31 December 2011, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement of accounting policies and other explanatory information, and the directors’ declaration of the consolidated entity comprising the disclosing entity and the entities it controlled at the half-year’s end or from time to time during the half-year.

Directors’ Responsibility for the Half-Year Financial Report

The directors of the disclosing entity are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity , in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the consolidated entity’s financial position as at 31 December 2011 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001 . As the auditor of Allied Healthcare Group Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the Corporations Act 2001 . We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Allied Healthcare Group Limited, would be in the same terms if given to the directors as at the time of this auditor’s report.

BDO Audit (WA) Pty Ltd ABN 79 112 284 787 is a member of a national association of independent entities which are all members of BDO (Australia) Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO Audit (WA) Pty Ltd and BDO (Australia) Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation (other than for the acts or omissions of financial services licensees) in each State or Territory other than Tasmania.

17

==> picture [76 x 29] intentionally omitted <==

Basis for Qualified Conclusion

Included in Allied Healthcare Group Limited’s consolidated statement of financial position as at 31 December 2011 is an investment of 37.27% in the associate Coridon Pty Limited which is accounted for under the equity method and is carried at $2,270,394. From the time Coridon Pty Limited became an associate, Allied Healthcare Group Limited’s share of the net loss is $344,961 which is included in the consolidated statement of comprehensive income for the period ended 31 December 2011. As the company is unaudited we were unable to obtain sufficient appropriate audit evidence to verify the valuation of the investment or its losses brought to account for the period and as such we were unable to determine whether any adjustments to these amounts are necessary. Given this limitation of scope we cannot, and do not express an opinion on the balance of investments or the result of the associate included in the consolidated statement of comprehensive income for the period ended 31 December 2011, or any consequential impact it may have on the carrying value of the investment.

Qualified Conclusion

Based on our review, which is not an audit, except for the effects of the matter described in the Basis for Qualified Conclusion paragraph, we have not become aware of any matter that makes us believe that the half-year financial report of Allied Healthcare Group Limited is not in accordance with the Corporations Act 2001 including:

  • (a) giving a true and fair view of the consolidated entity’s financial position as at 31 December 2011 and of its performance for the half-year ended on that date; and

  • (b) complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations Regulations 2001 .

BDO Audit (WA) Pty Ltd

==> picture [68 x 56] intentionally omitted <==

Brad McVeigh Director

Perth, Western Australia Dated this 29[th] day of February 2012

18